

CURRICULUM VITAE

NAME: Bertram L. Kasiske, M.D.

OFFICE ADDRESS: Department of Medicine
Hennepin County Medical Center
701 Park Avenue, Minneapolis, MN 55415
Telephone: 612/347-5871; Telefax: 612/347-2003

Division of Renal Diseases and Hypertension
Department of Medicine
University of Minnesota Medical School
MMC 736 Mayo, 420 Delaware Street S.E.
Minneapolis, MN 55455
Telephone: 612/624-9444; Telefax: 612/626-3840

DATE OF BIRTH: June 14, 1950

PLACE OF BIRTH: Keokuk, IA

EDUCATION:

1972 B.S. Michigan State University (Mathematics)
1976 M.D. University of Iowa School of Medicine

POSTDOCTORAL TRAINING:

Residency:

1976-1979 Internal Medicine, Hennepin County Medical Center, Minneapolis MN

1979-1980 Chief Medical Resident, Hennepin County Medical Center, Minneapolis MN

Clinical and Research Fellowship:

1980-1983 Nephrology, Hennepin County Medical Center, Minneapolis, MN

CERTIFICATION:

1980 Diplomate American Board of Medicine

1982 Diplomate American Board of Nephrology

Licensure: 1977-Current, Minnesota State Medical License #24449

ACADEMIC AND PROFESSIONAL APPOINTMENTS:

1983-Present	Staff Nephrologist, Hennepin Faculty Associates
1983-1989	Assistant Professor of Medicine, University of Minnesota
1989-1994	Associate Professor of Medicine, University of Minnesota
1994-Current	Professor of Medicine, University of Minnesota
1995-Current	Director, Division of Nephrology, Hennepin County Medical Center
2002-Current	Director, Transplant Nephrology, University of Minnesota
2002-Current	Editor-in-Chief, <i>American Journal of Kidney Diseases</i> Official journal of the National Kidney Foundation (WB Saunders)

AWARDS AND HONORS:

Phi Beta Kappa
Central Society for Clinical Research
Editorial Board, *American Journal of Kidney Diseases*, 1997 - 2001
Associate Editor, *Journal of Nephrology*, 1997 - 2001
Outstanding Research Accomplishment Award, Department of Medicine, School of Medicine,
University of Minnesota, May 2002
National Kidney Foundation's Garabed Eknoyan Award, 2003

COMMITTEE ASSIGNMENTS 1996 - Current:

2003-2006	Awards Committee, American Society of Transplantation
2002-2004	Medical/Scientific Representative, Board of Director, United Network for Organ Sharing (UNOS)
2000-2002	Chair, K/DOQI Working Group for Clinical Practice Guidelines for the Management of Dyslipidemia
2000-2001	Co-Chair, Program Committee, Clinical Nephrology Meetings 2001, National Kidney Foundation, Orlando, FL
1998-1999	RPA/ASN Working Group to develop guidelines on discontinuation of dialysis
1998-2000	Chair, Research Priorities Subcommittee of the American Society of Nephrology Clinical Sciences Committee
1997-1998	National Kidney Foundation Task Force on Cardiovascular Disease

1997-1999	Secretary/Treasurer, American Society of Transplantation
1996-1999	Member of the Board of Director, American Society of Transplantation
1995-current	Clinical Practice Guidelines Committee, American Society of Transplantation (Chair, 1995-2001)
1989-2000	Patient Care and Education Committee, American Society of Transplantation (Co-Chairman, 1991-1993; Chairman, 1993-1994)

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

American College of Physicians (Fellow)
American Society of Nephrology
American Society of Transplantation
National Kidney Foundation
International Society of Nephrology

RESEARCH SUPPORT, 1997-Current:

Principal Investigator: Immunosuppression Withdrawal in Stable Renal Allograft Recipients Treated with Triple Therapy. Roche Pharmaceutical Research, \$247,385, 1997-2001

Deputy Director: United States Renal Data System (USRDS), National Institutes of Health, 1999 – present.

VISITING PROFESSORSHIPS AND INVITED LECTURES IN 2001 - 2003:

1. “Can We Prevent Posttransplant Cardiovascular Disease?” Third Annual Canadian Transplant Advisory Forum – Optimizing Patient Management, Tucson, AZ, January 25-28, 2001.
2. “What Can We Do Now for Chronic Allograft Failure?” Canadian Society of Transplantation Annual Meeting, Lake Louise, Alberta, March 15-17, 2001.
3. “Cardiovascular Disease in Organ Recipients,” Canadian Society of Transplantation Annual Meeting, Lake Louise, Alberta, March 15-17, 2001.
4. “Preventing Cardiovascular Disease after Renal Transplantation”, (Co-Chair), Satellite Symposium, National Kidney Foundation Clinical Meeting, Orlando, FL, April 21, 2001.
5. “Evidence that post-transplant cardiovascular disease can be prevented,” Clinical Science Symposium: Clinical practice Guidelines: The Prevention of Medical Complications after Renal Transplantation. AST 2001, Annual Meeting of the American Society of Transplantation, Chicago, May 14, 2001.

6. "Management of Dislipidemia in Renal Patients," Hines VA Hospital, Chicago, May 22, 2001.
7. "Cardiovascular Assessment of Pre-transplant Patients," Provincial Renal Meeting, British Columbia Transplant Society, Vancouver, BC, June 8, 2001.
8. "Post-Transplant Outcomes: Data from the USRDS," Provincial Renal Meeting, British Columbia Transplant Society, Vancouver, BC, June 8, 2001.
9. "Prevention of Posttransplant Cardiovascular Disease," Fourth International Symposium on Renal Transplantation, Aguascalientes, Mexico, August 3-4, 2001.
10. "Preemptive Renal Transplantation," Fourth International Symposium on Renal Transplantation, Aguascalientes, Mexico, August 3-4, 2001.
11. "Recommendations for the Outpatient Surveillance of Renal Transplant Recipients," Fourth International Symposium on Renal Transplantation, Aguascalientes, Mexico, August 3-4, 2001.
12. "Patient Survival: The Importance of Cardiovascular Disease Risk Factors," "Satellite Symposium: Immunosuppression in the 21st Century – Redefining the Endpoints, European Society of Organ Transplantation Annual Meeting, Lisbon, Portugal, October 7, 2001.
13. "Trial Design for Interventional Studies," European Society of Organ Transplantation Annual Meeting, Lisbon, Portugal, October 11, 2001.
14. "Practice Guidelines for the Outpatient Follow-up of transplant Recipients," Postgraduate Education Course: Post-Transplant Complications, World Congress of Nephrology, Joint Meeting of the American Society of Nephrology and the International Congress of Nephrology, San Francisco, CA, October 13, 2001.
15. "Pathogenesis and Management of Hyperlipidemia in Renal Transplantation," World Congress of Nephrology, Joint Meeting of the American Society of Nephrology and the International Congress of Nephrology, San Francisco, CA, October 14, 2001.
16. "Diabetes in the Renal Transplant Patient Population," USRDS Presentation at the World Congress of Nephrology, Joint Meeting of the American Society of Nephrology and the International Congress of Nephrology, San Francisco, CA, October 16, 2001.
17. "Can Clinical Endpoints be Used Across All Organs?" AST/ASTS endpoints Conference, Bethesda, MD, November 5-6, 2001.
18. "Withdrawal of Immunosuppressive Drugs – Implications for the Long Term Function of Kidney Allografts," Third Adlon-Conference on Organ Transplantation, Berlin, Germany, November 9-11, 2001.
19. "Cardiovascular Problems after Renal Transplantation – Pathogenesis and Treatment," Dialysis Symposium, Stuttgart, Germany, December 8, 2001.
20. "Post-Transplant Diabetes," Nephrology Conference, Duke University, Durham, NC, January 11, 2002.

21. "Impact of New K/DOQI Guidelines: Dyslipidemia," International Conference on Dialysis IV – Advances in ESRD: 2002, Phoenix, AZ, January 25, 2002.
22. "Immunosuppression Withdrawal after Kidney Transplantation," California Pacific Medical Center, San Francisco, CA, February 8, 2002.
23. "Inadequate Nephron Dosing in Kidney Transplantation: Fact or Fallacy," Baylor College of Medicine, March 6, 2002.
24. "Inadequate Nephron Dosing: Fact or Fallacy," Controversies in Transplantation, University of Colorado School of Medicine, Breckenridge, CO, March 8, 2002.
25. "The Role of Cardiovascular Risk Factors in Chronic Allograft Nephropathy," Canadian Society of Nephrology, Ottawa, Canada, March 18, 2002.
26. "Hypercholesterolemia: How to Avoid, How to Control?" Cardiovascular/Medical Issues in Transplantation Session, NKF Clinical Nephrology Meetings 2002, Chicago, IL, April 19, 2002.
27. "Dyslipidemia Guidelines," NKF International Medals and K/DOQI Update Session, NKF Clinical Nephrology Meetings 2002, Chicago, IL, April 20, 2002.
28. "Major Causes of Mortality: Prolonging Life after Transplantation," American Transplant Congress 2002, Washington DC, May 1, 2002.
29. "Access to Databases for Transplant," American Transplant Congress 2002, Washington DC, April 29, 2002.
30. "Predictors of Long-Term Graft Survival and Opportunities for Intervention," ATC Satellite Symposium, Washington DC, April 29, 2002.
31. "Cardiovascular Disease after Transplantation," XXI Congress, Scandinavian Transplantation Society, Reykjavik, Iceland, May 23-24, 2002.
32. "Major Causes of Mortality: Prolonging Life after Kidney Transplantation," Second Annual Transplantation Symposium, Tokyo, Japan, June 1, 2002.
33. "Beyond Acute Rejection," University of Massachusetts, Worcester, MA, June 20, 2002.
34. "Intervention Studies in Cardiovascular Disease: Past, Present and Future," International Congress on Mechanisms of Uremic Toxicity, Wuerzburg, Germany, September 15, 2002.
35. "Cancer Surveillance in Transplantation," Transplant Atlantic 2002, Halifax, Nova Scotia, October 3, 2002.
36. "Best Practice Guidelines for Access to Transplantation," Transplant Atlantic 2002, Halifax, Nova Scotia, October 4, 2002.
37. "Long-Term Outcomes (USRDS Report)," Current Issues in Kidney Transplantation, Palm Springs,

CA, October 11, 2002.

38. "Managing the Risk of Cardiovascular Disease after Kidney Transplantation," Renal & Pancreas Transplant Symposium, UCLA School of Medicine, Los Angeles, CA, October 19, 2002.
39. "Management of Hyperlipidemia," Care of the Well-Transplant Patient Session, ASN Renal Week 2002, Philadelphia, PA, November 2, 2002.
40. "New Guidelines on Lipids," New K/DOQI Guidelines 2002 Symposium, ASN Renal Week 2002, Philadelphia, PA, November 2, 2002.
41. "Impact of Acute Rejection on Renal Allograft Function and Survival," Long-Term Outcomes in Renal Transplantation Session, ASN Renal Week 2002, Philadelphia, PA, November 3, 2002.
42. "Epidemiology of Cardiovascular Disease after Renal Transplantation: Lessons Learned from Retrospective Studies," Third Annual Canadian Transplant Forum, Toronto, Canada, November 24, 2002.
43. "Is the Kidney a Silent Partner in the Pathogenesis of Cardiovascular Disease?" Medicine Grand Rounds, Vanderbilt University, Nashville, TN, January 16, 2002.
44. "Lipids – Impact on More than CV Risk," Transplant Advisory Forum V – The State of the Art, Half Moon Bay, Jamaica, January 24, 2003.
45. "Markers of Declining Renal Function," Transplant Advisory Forum V – The State of the Art, Half Moon Bay, Jamaica, January 24, 2003.
46. "Cardiovascular Disease in Kidney Transplant Recipients," International Conference on Dialysis V – Advances in ESRD 2003, Miami Beach, FL, January 30, 2003.
47. "Does Mild-to-Moderately Reduced Kidney Function Contribute to Cardiovascular Disease Risk?" NIH Roundtable Symposium, Implications of Preserving Long-Term Renal Function after Renal Transplantation, Bethesda MD, November 10-11, 2003.

BIBLIOGRAPHY:

JOURNALS (Peer Reviewed):

1. Kasiske BL and Napier J: Glomerular sclerosis in patients with massive obesity. *Am J Nephrol* 5:45-50, 1985.
2. Kasiske BL, O'Donnell MP, Keane WF: Glucose-induced increases in renal hemodynamic function: Possible modulation by renal prostaglandins. *Diabetes* 34:360-364, 1985.
3. O'Donnell MP, Michels L, Kasiske B, Raij L, Keane WF: Adriamycin-induced chronic proteinuria: A structural and functional study. *J Lab Clin Med* 106(1):62-67, 1985.

4. O'Donnell MP, Kasiske BL, Raji L, Keane WF: Age is a determinant of the glomerular morphologic and functional responses to chronic nephron loss. *J Lab Clin Med* 106:308-313, 1985.
5. Kasiske BL, Cleary MP, O'Donnell MP, Keane WF: Effects of genetic obesity on renal structure and function in the Zucker rat. *J Lab Clin Med* 106:598-604, 1985.
6. O'Donnell MP, Kasiske BL, Cleary MP, Keane WF: Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. *J Lab Clin Med* 106:605-610, 1985.
7. Kasiske BL and Umen AJ: The influence of age, sex, race and body habitus on kidney weight in humans. *Arch Pathol Lab Med* 110:55-60, 1986.
8. Kasiske BL, Cleary MP, O'Donnell MP, Keane WF: Effects of carbohydrate restriction on renal injury in the obese Zucker rat. *Am J Clin Nutr* 44:56-65, 1986.
9. Kasiske BL and Crosson JT: Renal disease in patients with massive obesity. *Arch Int Med* 146:1105-1109, 1986.
10. Kasiske BL, O'Donnell MP, Keane WF: Renal effects of angiotensin II: Modulation by calcium and cyclooxygenase products. *Am J Physiol* 251:1043-1048, 1986.
11. O'Donnell MP, Kasiske BL, Daniels FX, Keane WF: Effects of nephron loss on glomerular hemodynamics and morphology in diabetic rats. *Diabetes* 35:1011-1015, 1986.
12. Kasiske BL: Relationship between vascular disease and age-associated changes in the human kidney. *Kidney Int* 31:1153-1159, 1987.
13. Kasiske BL, O'Donnell MP, Keane WF: The obese Zucker rat model of glomerular injury in type II diabetes. *J Diabetic Complications* 1:26-29, 1987.
14. O'Donnell MP, Kasiske BL, Daniels FX, Keane WF: Glomerular hemodynamic function in long-term diabetic rats with systemic hypertension. *J Hypertension* 4:S248-S250, 1987.
15. Luke DR, Kasiske B, Matzke GR, Awni WM, Keane WF: Effects of cyclosporine on the isolated perfused rat kidney. *Transplantation* 43:795-799, 1987.
16. Cleary MP, Kasiske B, O'Donnell MP, Keane WF: Effect of long-term clofibrate treatment on serum and tissue lipid and cholesterol levels in obese Zucker rats. *Atherosclerosis* 66:107-112, 1987.
17. Kasiske BL: Possible causes and consequences of hypertension in stable renal transplant patients. *Transplantation* 44:639-643, 1987.
18. Kasiske BL, O'Donnell MP, Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in the rat 5/6 nephrectomy model of chronic renal failure. *Circ Res* 62:367-374, 1988.
19. Kasiske BL: Persistent hyperlipidemia in renal transplant patients. *Medicine* 66:309-316, 1988.

20. Kasiske BL: The influence of donor age on renal function in transplant patients. *Am J Kidney Dis* 11:248-253, 1988.
21. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. *Kidney Int* 33:667-672, 1988.
22. O'Donnell MP, Kasiske BL, Keane WF: Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. *FASEB* 2:2339-2347, 1988.
23. Kasiske BL: Risk factors for accelerated atherosclerosis in renal transplant recipients. *Am J Med* 84:985-992, 1988.
24. Kasiske BL, Heim-Duthoy K, Rao KV, Awni WM: The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. *Transplantation* 46:716-722, 1988.
25. Kasiske BL, O'Donnell MP, Keane WF: Direct effects of altered temperature on renal structure and function. *Renal Physiol* 11:80-88, 1988.
26. O'Donnell MP, Kasiske BL, Keane WF: Risk factors for glomerular injury in rats with genetic hypertension. *Am J Hypertension* 2:9-13, 1989.
27. Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV: Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: Effects of binding and metabolism. *Clin Pharmacol Ther* 45:41-48, 1989.
28. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF: Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic obese Zucker rats. *Kidney Int* 35:40-47, 1989.
29. Rao KV, Kasiske BL, Bloom PM: Acute graft rejection in the late survivors of renal transplantation: clinical and histologic observations in the second decade. *Transplantation* 47:290-292, 1989.
30. Kasiske BL, O'Donnell MP, Keane WF: Fish oil diet decreases prostacyclin and increases resistance in isolated rat kidneys. *Am J Physiol* 256 (Renal Fluid Electrolyte Physiol 25):F843-F851, 1989.
31. Kasiske BL: Creatinine excretion after renal transplantation. *Transplantation* 48:424-427, 1989.
32. Kasiske BL, Heim-Duthoy KL, Tortorice KL, Ney A, Odland M, Rao KV: Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. *Arch Int Med* 149:2733-36, 1989.
33. Kasiske BL, Velosa JA, Halstenson CE, LaBelle P, Langend'rfer A, Keane WF: The effects of Lovastatin in hyperlipidemic patients with the nephrotic syndrome. *Am J Kidney Dis* 15:8-15, 1990.
34. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Goryance JM, Rao KV: Lovastatin treatment of hypercholesterolemia in renal transplant recipients. *Transplantation* 49:91-95, 1990.
35. Rao KV, Kasiske BL, Odland MD, Ney AL, Andersen RC: The influence of cadaver donor age on

- post-transplant renal function and graft outcome. *Transplantation* 49:95-100, 1990.
36. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF: The renal injury of diet-induced hypercholesterolemia. *Kidney Int* 37:880-891, 1990.
 37. O'Donnell MP, Kasiske BL, Keane WF: High protein intake accelerates glomerulosclerosis independent of effects on glomerular hemodynamics. *Kidney Int* 37:1263-1269, 1990.
 38. Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV, Kasiske BL: The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients. *Ther Drug Monit* 12:321-28, 1990.
 39. Kasiske BL, Heim-Duthoy KL, Tortorice K, Rao KV: The variable nature of chronic declines in renal allograft function. *Transplantation* 51:330-334, 1991.
 40. Rao, KV, Kasiske BL, Anderson WR. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. *Transplantation* 51:391-396, 1991.
 41. Kasiske BL, Neylan JF, Riggio RR, Danovich GM, Kahana L, Alexander S, White MG: The effect of race on access and outcome in transplantation. *N Engl J Med* 324:302-307, 1991.
 42. Kasiske BL, O'Donnell MP, Lee HS, Kim Y, Keane WF: The impact of dietary fatty acid supplementation on renal injury in obese Zucker rats. *Kidney Int* 39:1125-1134, 1991.
 43. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV: The adverse impact of cyclosporine on serum lipids in renal transplant recipients. *Am J Kidney Dis* 17:700-707, 1991.
 44. Kasiske BL, Keane WF: The role of lipid peroxidation in the inhibition of mononuclear cell proliferation by normal lipoproteins. *J Lipids Res* 32:775-781, 1991.
 45. Schmitz PG, O'Donnell MP, Kasiske BL, Keane WF: Glomerular hemodynamic effects of dietary polyunsaturated fatty acid supplementation. *J Lab Clin Med* 118:129-135, 1991.
 46. Kasiske BL, Kalil RSN, Lee H, Rao KV: Histopathologic findings associated with a chronic, progressive decline in renal allograft function. *Kidney Int* 40:514-524, 1991.
 47. Kalil RS, Heim-Duthoy KL, Kasiske BL: Patients with a low income have reduced renal allograft survival. *Am J Kidney Dis* 20:63-69, 1992.
 48. Kasiske BL, Heim-Duthoy KL: Transient reductions in serum cholesterol after renal transplantation. *Am J Kidney Dis* 20:387-393, 1992.
 49. Schmitz PG, O'Donnell MP, Kasiske BL, Katz SA, Keane WF: Renal injury in obese Zucker rats: glomerular hemodynamic alterations and the effects of enalapril. *Am J Physiol* 263 (Renal Fluid Electrolyte Physiol 32):F496-F502, 1992.
 50. O'Donnell MP, Kasiske BL, Katz SA, Schmitz PG, Keane WF: Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. *Hypertension* 20:651-658, 1992.

51. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-analysis. *Ann Intern Med* 118:129-138, 1993.
52. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF: Lovastatin inhibits proliferation of rat mesangial cells. *J Clin Invest* 91:83-87, 1993.
53. Kasiske BL, Heim-Duthoy KL, Ma J: Elective cyclosporine withdrawal after renal transplantation: A meta-analysis. *JAMA* 269:395-400, 1993.
54. Rao KV, Anderson WR, Kasiske BL, Dahl DC. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. *Am J Med* 241-250, 1993.
55. Fioretto P, Keane WF, Kasiske BL, O'Donnell MP, Klein DJ: Alterations in glomerular proteoglycan metabolism in experimental non-insulin dependent diabetes mellitus. *J Am Soc Nephrol* 3:1694-1704, 1993.
56. Atluru D, Hansen J, Remick DG, O'Donnell MP, Kasiske BL, Keane WF. Effects of cyclosporin A, FK-506 and genistein on IL-6, IL-8 production and gene expression by human mononuclear cells. *Biochemical Archives* 9:147-155, 1993.
57. O'Donnell MP, Kasiske BL, Kim Y, Schmitz P, Keane WF. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. *Am J Kidney Dis* 22:83-89, 1993.
58. Keane WF, O'Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low density lipoproteins by mesangial cells. *J Am Soc Nephrol* 4:187-194, 1993.
59. Chitwood KK, Heim-Duthoy KL, Ney AL, Kasiske BL. Questionable benefit of prophylactic acyclovir in renal transplant recipients at high risk for cytomegalovirus disease. *Clin Transplantation* 7:320-324, 1993.
60. Hirata-Dulas CAI, Halstenson CE, Kasiske BL: Improvement in the accuracy and precision of creatinine clearance as a measure of glomerular filtration rate with oral cimetidine in renal transplant recipients. *Clin Transplantation* 7:552-558, 1993.
61. Harker CT, O'Donnell MP, Kasiske BL, Keane WF, Katz SA: The renin angiotensin system in the type II diabetic obese Zucker rat. *J Am Soc Nephrol* 4:1354-1361; 1993.
62. Ramos EL, Kasiske BL, Alexander S, Danovitch GM, Harmon WE, Kahana L, Kiresuk TJ, Neylan JF: The evaluation of candidates for renal transplantation: the current practice of US transplant centers. *Transplantation* 57:490-497; 1994.
63. Heim-Duthoy KL, Chitwood KK, Tortorice KL, Kasiske BL. Elective cyclosporine withdrawal one year after renal transplantation. *Am J Kidney Dis* 24:846-853, 1994.
64. Atluru D, O'Donnell MP, Guijarro C, Kasiske BL, Gudapaty S, Keane WF. Human mononuclear cell proliferation, but not interleukin-6 production, is dependent on isoprenoid products of mevalonate metabolism. *Biochem Arch* 10:67-78, 1994.

65. Kasiske BL, Ma JZ, Kalil RSN, Louis T. Effects of antihypertensive therapy on serum lipids. *Ann Intern Med* 122:133-141, 1995.
66. Lum CT, Umen AJ, Kasiske BL, Goerd P, Heim-Duthoy KL, Andersen RC, Odland MD, Ney AL, Jacobs DM, Rao KV, Pavel D. Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM. *Transplantation* 59:371-376, 1995.
67. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. *Arch Intern Med* 155:1073-1080, 1995.
68. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF. Early glomerular changes in rats with dietary-induced hypercholesterolemia. *Am J Kidney Dis* 26:152-161, 1995.
69. Kim S-Y, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF. Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. *Kidney Int* 48:363-371, 1995.
70. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. *Kidney Int* 48:188-198, 1995.
71. Kasiske BL, Ma JZ, Louis TA, Swan SK. Long-term effects of reduced renal mass in humans. *Kidney Int* 48:814-819, 1995.
72. Bia MJ, Ramos EL, Danovitch GM, Gaston RS, Harmon WE, Leichtman AB, Lundin PA, Neylan J, Kasiske BL. Evaluation of living renal donors. The current practice of US transplant centers. *Transplantation* 60:322-327, 1995.
73. Kasiske BL, Bia MJ. The evaluation and selection of living kidney donors. *Am J Kidney Dis* 26:387-398, 1995.
74. Kasiske BL, Ramos EL, Gaston RS, Bia MJ, Danovitch GM, Bowen PA, Lundin PA, Murphy KJ. The evaluation of renal transplant candidates: Clinical Practice Guidelines. *J Am Soc Nephrol* 6:1-34, 1995.
75. Swan SK, Crary GS, Guijarro C, O'Donnell MP, Keane WF, Kasiske BL. Immunosuppressive effects of leflunomide in experimental chronic vascular rejection. *Transplantation* 60:887-890, 1995.
76. Crary GS, Swan SK, O'Donnell MP, Kasiske BL, Katz SA, and Keane WF. The angiotensin II antagonist, losartan, reduced blood pressure but not renal injury in obese Zucker rats. *J Am Soc Nephrol* 6:1295-1299, 1995.
77. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. *JASN* 7:158-165, 1996.
78. Swan SK, Halstenson CE, Kasiske BL, Collins AJ. Determination of residual renal function with iohexol clearance in hemodialysis patients. *Kidney Int* 49:232-235, 1996.
79. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors. *Kidney Int* 49:518-524, 1996.

80. Hirata-Dulas CAI, Rith-Najarian SJ, McIntyre MC, Ross C, Dahl DC, Keane WF, Kasiske BL. Risk factors for nephropathy and cardiovascular disease in diabetic Northern Minnesota American Indians. *Clin Nephrol* 46:92-98, 1996.
81. Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ, Kasiske BL. Serum albumin and mortality after renal transplantation. *Am J Kidney Dis* 27(1):117-123, 1996.
82. Kasiske BL, Ravenscraft M, Ramos EL, Gaston RS, Bia MJ, Danovitch GM. The evaluation of living renal transplant donors: Clinical Practice Guidelines. *J Am Soc Nephrol* 7:2288-2313, 1996.
83. Moore RR, Jr, Hirata-Dulas CA, Kasiske BL. The use of urine specific gravity to improve screening for albuminuria. *Kidney Int* 52:240-243, 1997.
84. Kasiske BL, Johnson HJ, Goerdts PJ, Heim-Duthoy Rao VK, Dahl DC, Ney AL, Andersen RC, Jacobs DM, Odland MD. A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients. *Am J Kidney Dis* 30(5):639-645, 1997.
85. Park Y-S, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, O'Donnell MP. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. *Am J Kidney Dis* 31(1):190-194, 1997.
86. O'Donnell MP, Chao CC, Gekker G, Modi KS; Kasiske BL; Keane WF. Renal cell cytokine production stimulates HIV-1 expression in chronically HIV-1-infected monocytes. *Kidney Int* 53(3):593-597, 1998.
87. Kasiske BL, Lakatua JDA, Ma JZ, Louis T. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. *Am J Kidney Dis* 31(6):954-961, 1998.
88. Kasiske BL, Chakkera H. Successful renal transplantation in high-risk American Indians. *Transplantation* 66(2):209-214, 1998.
89. Consensus Conference on Standardized Listing Criteria for Renal Transplant Candidates (NIH and American Society of Transplant Physicians). *Transplantation* 66(7):962-967, 1998.
90. Kasiske BL, Rith-Najarian S, Casper ML, Croft, JB. American Indian heritage and risk factors for renal injury. *Kidney Int* 54:1305-1310, 1998.
91. Kasiske BL. Hyperlipidemia in Patients with Chronic Renal Disease. *Am J Kidney Dis* 32(5)(Suppl 3): S142-S156, 1998.
92. Kasiske BL, London W, Ellison MD. Race and socioeconomic factors influencing early placement on the kidney transplant waiting list. *J Am Soc Nephrol* 9:2142-2147, 1998.
93. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, and Wright JT, Jr. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. *Am J Kidney Dis* 32 (5):853-906, 1998.

94. Danpanich E and Kasiske BL. Risk factors for cancer in renal transplant recipients. *Transplantation* 68:1859-1864, 1999.
95. Neugarten J, Gallo G, Silbiger S, and Kasiske B. Glomerulosclerosis in aging humans is not influenced by gender. *Am J Kidney Dis* 34 (5):884-888, 1999.
96. Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. *J Am Soc Nephrol* 11:753-759, 2000.
97. Kasiske BL, Chakkerla HA, Louis TA, and Ma JZ. A Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation. *J Am Soc Nephrol* 11 (10):1910-1917, 2000.
98. Kasiske BL, Chakkerla HA, and Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. *J Am Soc Nephrol* 11 (9):1735-1743, 2000.
99. Kasiske BL, Cohen D, Lucey MR, and Neylan JF. Payment for immunosuppression after organ transplantation. American Society of Transplantation. *JAMA* 283 (18):2445-2450, 2000.
100. Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, and O'Donnell MP. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. *Biochem Biophys Res Commun*. 267 (2):536-540, 2000.
101. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG: Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. *J Am Soc Nephrol* 11 Suppl 15:S1-86, 2000.
102. Fried L, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. *Kidney Int* 59:260-269, 2001.
103. Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ, Bastani B. The Effects of Lipid-Lowering Agents on Acute Renal Allograft Rejection. *Transplantation* 72(2):223-227, 2001.
104. Hernandez D, Hanson E, Kasiske M, Danielson B, Roel J, Kasiske BL. Cytomegalovirus disease is not a major risk factor for ischemic heart disease after renal transplantation. *Transplantation* 72(8): 1395-1399, 2001.
105. Kasiske BL, Andany MA, Hernandez D, Silkensen J, Rabb H, McClean J, Roel JP, Danielson B: Comparing methods for monitoring serum creatinine to predict late renal allograft failure. *Am J Kidney Dis* 38: 1065-1073, 2001.
106. Nemoto T, Burne MJ, Daniels F, O'Donnell MP, Crosson J, Berens K, Issekutz A, Kasiske BL, Keane WF, Rabb H. Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. *Kidney Int* 60(6): 2205-2214, 2001.
107. Kasiske BL, Snyder J: Matching older kidneys with older patients does not improve allograft survival. *J Am Soc Nephrol* 13(4): 1067-1072, 2002.

108. Kasiske BL, Snyder JJ, Matas AJ, Ellison MD, Gill JS, Kausz AT. Preemptive kidney transplantation: The advantage and the advantaged. *J Am Soc Nephrol* 13:1358-1364, 2002.
109. Anjum S, Adeva Andany M, McClean JC, Danielson B, Kasiske BL. Defining the risk of elective cyclosporine withdrawal in stable kidney transplant recipients. *Am J Transplantation* 2:179-185, 2002.
110. Kasiske BL, Adeva Andany M, Danielson B. A Thirty Percent Chronic Decline in Inverse Serum Creatinine is an Excellent Predictor of Late Renal Allograft Failure. *Am J Kidney Dis* 39(4):762-768, 2002.
111. Neugarten J, Kasiske B, Silbiger SR, Nyengaard JR. Effects of sex on renal structure. *Nephron* 90(2):139-144, 2002.
112. Kasiske BL, Snyder JJ, Gilbertson D. Inadequate donor size in cadaver kidney transplantation. *J Am Soc Nephrol* 13:2152-2159, 2002.
113. Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazquez MA, Weir MR. The evaluation of renal transplantation candidates: clinical practice guidelines. *Am J Transplant* 1 Suppl 2:1-95, 2002.
114. O'Shaughnessy EA, Dahl DC, Smith CL, Kasiske BL: Risk factors for fractures in kidney transplantation. *Transplantation* 74:362-366, 2002.
115. Qureshi F, Rabb H, Kasiske BL. Silent acute rejection during prolonged delayed graft function reduces kidney allograft survival. *Transplantation* 74:1400-1404, 2002.
116. Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, Rabb H. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. *Am J Nephrol* 23(1):13-17, 2002.
117. Snyder JJ, Kasiske BL, Gilbertson DT, Collins AJ. A comparison of transplant outcomes in peritoneal and hemodialysis patients. *Kidney Int.* 62(4):1423-1430, 2002.
118. Kasiske B: Managing dyslipidemias in chronic kidney disease. *Nephrol News Issues* 17:81-3, 93, 2003.
119. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. *Am J Transplant* 3:178-185, 2003.
120. Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, Rabb H. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. *Am J Nephrol* 23:13-17, 2003.

EDITORIALS, REVIEWS, BOOK CHAPTERS AND PROCEEDINGS:

1. Kasiske BL and Kjellstrand CM: Perioperative management of patients with chronic renal failure

- and postoperative acute renal failure. *Urol Clin of North Am* 10:(1)35-50, 1983.
2. Keane WF, Kasiske BL, O'Donnell MP: Hyperlipidemia and the progression of renal disease. *Am J Clin Nutr* 47:157-60, 1988.
 3. Keane WF, Kasiske BL, O'Donnell MP: The role of lipids in progressive renal injury. In: Advances in Experimental Medicine and Biology. Uremic Toxins. Vol. 223. S Ringoir, R Vanholder (eds). Plenum Publishing Corp., New York, NY, pp. 81-87, 1988.
 4. Keane WF, Kasiske BL, O'Donnell MP: Lipids and progressive glomerulosclerosis: A model analogous to atherosclerosis. *Am J Nephrol* 8:261-271, 1988.
 5. Awni WM, Kasiske B, Heim-Duthoy K, Rose M, Rao KV, Bloom P, Ney A, Andrisevic J, Odland M, Andersen RC: Changes in the pharmacokinetics of cyclosporine and three of its metabolites in renal transplant patients early in the post-transplant period. *Transplant Proc* 20:623-624, 1988.
 6. Kasiske BL, Awni WM, Heim-Duthoy KL, Rose M, Rao KV, Bloom P, Ney A, Andrisevic J, Odland M, Andersen RC: Alterations in cyclosporine pharmacokinetics+ after renal transplantations are linked to rapid increases in hematocrit, lipoproteins, and serum protein. *Transplant Proc* 20:485-486, 1988.
 7. Halstenson CE, Kasiske BL, Keane WF: Glomerulonephritis. Chapter 38. In: Pharmacotherapy: Principals of Therapeutics. Posey LM, DiPiro J, Talbert R, Hayes P, Yee G (eds). Elsevier Science Publishers BV, Amsterdam pp 578-588, 1989.
 8. Schmitz PG, Kasiske BL, O'Donnell MP, Keane WF: Lipids and progressive renal injury. *Semin Nephrol* 9:354-369, 1989.
 9. O'Donnell MP, Kasiske BL, Keane WF: Risk factors for glomerular injury in rats with genetic hypertension. *Am J Hypertens* 2:9-13, 1989.
 10. Keane WF, Kasiske BL, O'Donnell MP: Factors important in the progression of renal disease. In: ACE inhibitors: past, present and beyond. Clement DL (ed). Royal Society of Medicine Services International Congress and Symposium Series No. 144, published by Royal Society of Medicine Services Limited, pp. 37-41, 1989.
 11. Keane WF, Kasiske BL, O'Donnell MP, Schmitz PG: Therapeutic implications of lipid-lowering agents in the progression of renal disease. *Am J Med* 87:21N-24N, 1989.
 12. Kasiske BL, O'Donnell MP, Cowardin W, Keane WF: Lipids and the Kidney. *Hypertension* 15:443-450, 1990.
 13. Keane WF, Abraham PA, Kasiske BL, O'Donnell MP, Schmitz PG: Angiotensin converting enzyme inhibitors and progressive renal disease: An overview. Raven Press Ltd, New York, pp 59-66, 1990.
 14. Awni WM, Heim-Duthoy K, Kasiske BL: Monitoring of cyclosporine by serial post-transplant pharmacokinetic studies in renal transplant patients. *Transplant Proc* 22:1343-1344, 1990.

15. Awni WM, Heim-Duthoy K, Kasiske, BL: Impact of lipoproteins on cyclosporine pharmacokinetics and biological activity in transplant patients. *Transplant Proc* 22:1193-1196, 1990.
16. Keane WF, Kasiske BL: Hyperlipidemia in the nephrotic syndrome. (Editorial) *N Engl J Med* 323:603-604, 1990.
17. Keane WF, Kasiske BL, O'Donnell MP, Schmitz PG: Lipids and the progression of renal disease. *J Am Soc Neph* 1:S69-S74, 1990.
18. Rao KV, Odland M, Ney A, Andersen RC, Kasiske BL: Does the quality of early graft function influence the long-term outcome of cadaver renal transplantation? A case control study from a single institution. *Transplant Proc* 22:402, 1990.
19. Kasiske BL, O'Donnell MP, Keane WF: Mild hypothermia gives better functional preservation than cold or normothermic perfusion of rat kidneys. *Transplant Proc* 22:472-473, 1990.
20. Kasiske BL, Keane WF: Causes, consequences, and treatment of hyperlipidemia in patients with renal disease. In: 1991 International Yearbook of Nephrology. VE Andreucci, LG Fine (eds). Kluwer Academic Publishers, Boston, pp 179-196, 1991.
21. Keane WF, O'Donnell MP, Kasiske BL: Glomerular microcirculatory dynamics and their relationship to progressive renal disease: recent concepts. Medical Advisory Committee. In: Cardiac and Renal Failure: An Expanding Role for ACE Inhibitors. Hanley & Belfus, Philadelphia, PA, pp. 237-247, 1991.
22. Kasiske BL, O'Donnell MP, Schmitz P, Keane WF: The role of lipid abnormalities in the pathogenesis of chronic, progressive renal disease. In: Advances in Nephrology From the Necker Hospital. Vol. 20. Grhnfeld J-P, Bach JF, Funck-Bretitano JF and Maxwell MH (eds.), Mosby Yearbook, St. Louis, pp 109-126, 1991.
23. Kasiske BL, Heim-Duthoy KL, Rao KV. The clinical course of chronic declines in renal allograft function. *Transplant Proc* 23:1271, 1991.
24. Keane WF, Mulcahy WJ, Kasiske BL, Kim Y, O'Donnell MP. Hyperlipidemia and progressive kidney disease. *Kidney Int* 39(Suppl 31):S41-S48, 1991.
25. Keane WF, Kasiske BL, O'Donnell MP, Kim Y. The role of altered lipid metabolism in the progression of renal disease: experimental evidence. *Am J Kidney Dis* 27(5)Suppl 1:38-42, 1991.
26. Keane WF, Kasiske BL, O'Donnell MP. The role of lipid abnormalities in the pathogenesis of chronic progressive renal disease. In: Assessment and Management of Risks Associated with Hyperlipidemia, Osteoporosis, and Hepatitis-B: Effectiveness of Intervention. RG Douglas, M Hilleman (eds.). Hanley & Belfus, Publishers, pp 43-55, 1991.
27. Awni WM, Heim-Duthoy KL, Kasiske BL. Therapeutic monitoring of cyclosporine utilizing pharmacokinetic studies. *Clin Chem* 37:1891-1892, 1991.
28. Manske CL and Kasiske BL: Lipid abnormalities after renal transplantation. In: Contemporary

Issues in Nephrology Volume 24, Lipids and Renal Disease, WF Keane and JH Stein (eds).
Churchill Livingstone, New York, NY, pp 37-61, 1991.

29. Kasiske BL, O'Donnell MP, Keane WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. *Hypertension* 19(Suppl I):I110-I115, 1992.
30. Gray JR, Kasiske BL. Patient and renal allograft survival in the last post-transplant period. *Semin Nephrol* 12:343-352, 1992.
31. Kasiske BL. Atherosclerosis in organ transplant recipients. In: Organ Transplantation: Long-Term Results. Chapter 14. Paul and Solez (eds). Marcel Dekker, Publishers 1992, pp. 283-301.
32. Kasiske BL. Questions and answers from controlled clinical trials of antihypertensive therapy in progressive renal disease. *Am J Hypertension* 5:778-779, 1992.
33. Keane WF, St. Peter JV, Kasiske BL. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? *Kidney Int* 42 (Suppl 38):S-134-S-141, 1992.
34. Keane WF, Kasiske BL, O'Donnell MP. The role of lipid abnormalities in renal and vascular injury. *Nefrologia* 12(Suppl 5):42-48, 1992.
35. Kasiske BL, O'Donnell MP, Keane WF. Hyperlipidemia and chronic, progressive, renal disease. In: Pathophysiology of ARF Lipids and Kidney Diseases: The Heart in Renal Failure. Gd'Amico and G Colasanti (eds.), Wichtig Editore srl, Milano, Italy, 1992, pp. 65-71.
36. Kasiske BL, O'Donnell MP, Keane WF. The obese Zucker rat model of chronic, progressive glomerular injury. In: Experimental and Genetic Rat Models of Chronic Renal Failure. N Gretz and M Strauch (eds.), Karger:Basel, 1993, pp. 90-99.
37. Odland MD, Kasiske BL. Kidneys from female donors are at increased risk for chronic allograft rejection. *Transplant Proc* 25:912, 1993.
38. Keane WF, Kasiske BL, O'Donnell MP, Kim Y. Hypertension, hyperlipidemia, and renal damage. *Am J Kidney Dis* 21(Suppl 2): 43-50, 1993.
39. Halstenson CE, Kasiske BL, Keane WF. Glomerulonephritis. In: Pharmacotherapy: A Pathophysiologic Approach. 2nd ed., JT DiPiro, RL Talbert, PE Hayes, GE Yee, GR Matzke, LM Posey (eds), Appleton & Lange:Norwalk CT, 1993.
40. Heim-Duthoy KL, Kalil RSN, Kasiske BL. Acute Renal Failure. In: Pharmacotherapy: A Pathophysiologic Approach. 2nd ed., JT DiPiro, RL Talbert, PE Hayes, GE Yee, GR Matzke, LM Posey (eds), Appleton & Lange:Norwalk CT, 1993.
41. Kasiske BL. The effects of blood pressure treatment on the kidney in patients with diabetes mellitus. *West Indian Medical Journal* 42(Suppl 2): 3, 1993.
42. Kasiske BL, O'Donnell MP, Kim Y, Keane WF. Treatment of hyperlipidemia in chronic progressive renal disease. *Curr Opin Nephrol Hypertens* 2: 602-608, 1993.

43. Kasiske BL. Risk factors for cardiovascular disease after renal transplantation. *Miner Electrolyte Metab* 19:186-195, 1993.
44. O'Donnell MP, Kasiske BL, Keane WF. Effects of dietary fatty acids on experimental renal disease. In: Experimental and Genetic Rat Models of Chronic Renal Failure. Gretz N and Strauch M (eds.), Basel:Karger, 1993; p. 90-99.
45. O'Donnell MP, Kasiske BL, Atluru D, Kim Y, Keane WF. The mevalonate pathway: Importance in mesangial cell biology and glomerular disease. *Miner Electrolyte Metab* 19:173-179; 1993.
46. Markon CE, Kasiske BL. The use of antihypertensive agents in the management of patients with diabetic nephropathy. *Dialysis & Transplantation* 23:116-125, 1994.
47. Kasiske BL, O'Donnell MP, Kim Y, Atluru D, Keane WF. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis. *Kidney Int* 45(Suppl 45): S51-S53; 1994.
48. BL Kasiske. The effects of immunosuppressive agents on plasma lipoproteins after organ transplantation. (Editorial) *J Lab Clin Med* 124:318-319, 1994.
49. Massy ZA, Guijarro C, Kasiske BL. Plasma mevalonate and its importance in nephrology. *Nephrol Dialysis Transplant* 9:1716-1718, 1994.
50. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH, Steffes MW, Striker GE. Screening and management of microalbuminuria in patients with diabetes mellitus: Recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. *Am J Kidney Dis* 25:107-112, 1995.
51. Massy ZA, Guijarro C, Kasiske BL. Effect of fenofibrates in heart transplant patients. (Letter) *Transplantation* 59:451, 1995.
52. Kasiske BL, Keane WF. Laboratory assessment of renal disease: Clearance, urinalysis, and renal biopsy. In: The Kidney. Fifth Edition, BM Brenner and FC Rector, Jr. (eds), WB Saunders Company:Cambridge. Pages 1137-1174, 1996.
53. Massy ZA, Kasiske BL. The management of hyperlipidaemia in patients with renal disease. *In International Yearbook of Nephrology Dialysis Transplantation*, VE Andreucci and LG Fine (eds). *Nephrol Dialysis Transplant* 10(Suppl):117-125, 1995.
54. O'Donnell MP, Kasiske BL, Massy ZA, Guijarro C, Swan SK, Keane WF. Isoprenoids and Ras: Potential role in chronic rejection. *Am J Kidney Dis* 48(Suppl 52):S29-S33, 1995.
55. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. *Kidney Int* 48(Suppl 52):S56-S59, 1995.
56. Massy ZA, Guijarro C, Kasiske BL. Clinical predictors of chronic renal allograft rejection. *Kidney Int* 48(Suppl 52):S85-S88, 1995.
57. Kasiske BL, Massy ZA, Guijarro C, Ma JZ. Chronic renal allograft rejection clinical trial design.

- Kidney Int 48(Suppl 52):SI 16-SI 19, 1995.
58. Kasiske BL. Cyclosporine withdrawal after renal transplantation: does it affect graft loss? (Editorial). *J Nephrol* 8(2):65-66, 1995.
 59. Kasiske BL, Ma JZ, Keane WF. Effects of ACE inhibitors on proteinuria and renal function in diabetic nephropathy. *ACE Report*, Merck & Co., Inc., Whitehouse Station, NJ, 1995.
 60. Massy ZA, Kasiske BL. Hyperlipidemia and its management in renal disease. *Curr Opin Nephrol Hypertens* 5:141-146, 1996.
 61. Massy ZA, Keane WF, Kasiske BL. Benefits of mevalonate pathway inhibition: beyond cholesterol reduction. *Lancet* 347:102-103, 1996.
 62. Massy ZA, Kasiske BL. Post-transplant hyperlipidemia: mechanisms and management. *J Am Soc Nephrol* 7:971-977, 1996.
 63. Kasiske BL. Dialysis in special clinical situations: anesthesia. *In Replacement of Renal Function by Dialysis*. Jacobs C, Kjellstrand C, Koch K, Winchester JF (ed), Kluwer Academic Publishers:Dordrecht, The Netherlands; 1996, page 954-965.
 64. Marine KA, Kasiske BL. Nutritional management of renal transplantation (Chapter 22). *In Nutritional Management of Renal Disease*, Kopple JD and Massry SG (eds), Williams & Wilkins:Baltimore. Pages 669-685, 1996.
 65. Neylan J, Kasiske BL. Renal transplantation. *In Self Assessment Colour Review of Renal Medicine*. 1996.
 66. Massy ZA, O'Donnell MP, Kasiske BL, Keane WF. Regulation of mesangial cell proliferation by the mevalonate pathway. In: *The Role of Lipids in the Progression of Renal Disease – Experimental Studies. Contributions to Nephrology*. Pages 191-196, 1996.
 67. Kasiske BL. The Role of Diet in Chronic Renal Disease Progression. Proceedings of the Symposium on *Diet, Nutrition and Health: An Update*, London, Ontario, June 16-17, 1996.
 68. Kasiske BL. Meta-Analytic Review of Studies Investigating the Effects of Antihypertensive Agents on the Kidney. Proceedings of the 6th Verona Seminar on Nephrology, September 1996. In: *Basi Fisiopatologiche ed Attualità Clinico - Terapeutiche Delle Nefropatie*, L Maschio (ed). Wichtig Editore:Milano, 1997. Pages 99-107.
 69. BL Kasiske and WF Keane. Renal Diagnostic Testing: Past, Present and Future. (Editorial) *Curr Opin Nephrol Hyperten* 5:519-520, 1996.
 70. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? *Lancet* 347:102-103, 1996.
 71. Kobashigawa JA and Kasiske BL. Hyperlipidemia in solid organ transplantation. *Transplantation* 63:331-338, 1997.

72. Kasiske BL, The Evaluation of Prospective Renal Transplant Recipients. In *NKF Primer. A* Greenberg (ed.), Academic Press, San Diego, Chapter 74, pages 477-481, 1997.
73. Keane WF and Kasiske BL. The renal cardiovascular axis: new diagnostic insights. (Editorial) *Curr Opin Nephrol Hyperten* 6:551-552, 1997.
74. Kasiske BL, Lakatua JDA. The Effects of Dietary Protein Restriction on Chronic Progressive Renal Disease. Proceedings of the 8th International Congress in Napoli, Italy, October 9-12, 1996. *Miner Electrolyte Metab* 23:296-300, 1997.
75. Kasiske BL. Clinical correlates to chronic renal allograft rejection. *Kidney Int* 52(Suppl 63): S-71 – S-74, 1997.
76. Kasiske BL. Immune and nonimmune clinical correlates of chronic renal allograft rejection. *Transplant Proc* 29(6):2557, 1997.
77. O'Donnell MP; Massy ZA; Guijarro C; Kasiske BL; Kim Y; Keane WF. Isoprenoids, Ras and proliferative glomerular disease. *Contrib Nephrol* 120:219-27, 1997.
78. Guijarro C; Kim Y; Kasiske BL; Massy ZA; O'Donnell MP; Kashtan CE; Keane WF. Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines. *Contrib Nephrol* 120:210-8, 1997.
79. Grimm RH Jr; Svendsen KH; Kasiske B; Keane WF; Wahi MM. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. *Kidney Int Suppl* 63:S10-4, 1997.
80. O'Donnell MP; Crary GS; Oda H; Kasiske BL; Powell JR; Keane WF. Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. *Kidney Int Suppl* 63:S218-220, 1997.
81. Kasiske BL. The evaluation of prospective renal transplant recipients and living donors. *Surg Clin North Am* 78(1):27-39, 1998.
82. Kasiske BL and JZ Ma. A Clinician's Guide to Meta-Analysis in Nephrology. In Brady & Wilcox (eds), *Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's The Kidney*. 1997.
83. Massy ZA, Guijarro C, O'Donnell MP, Kasiske BL, Keane WF. Lipids, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, and progression of renal failure. *Adv Nephrol Necker Hosp* 27:36-56, 1997.
84. BL Kasiske. Cyclosporine and lipid peroxidation (Journal Club). *Am J Kidney Dis* 31:149-151, 1998.
85. Kasiske BL. Management of lipid abnormalities in the patient with renal disease. In *Handbook of Nutrition and the Kidney*, edited by Mitch WE and Klahr S. Lippincott-Raven Publishers: Philadelphia, 1998, pages 123-143.

86. Kasiske BL. Meta-analysis as a clinical tool in nephrology. *Kidney Int* 53:819-825, 1998.
87. Kasiske BL, London W, Ellison M. Factors influencing early placement on the kidney transplant waiting list in the United States. In JL Touraine et al (eds), *Organ Allocation*, Kluwer Academic Publishers: London, 1998; pages 135-137.
88. Kasiske BL. Cyclosporine: Clinical Use in Kidney Transplantation. In LC Racusen, K Solez, JF Burdick (eds), *Kidney Transplant Rejection – Diagnosis and Treatment*, 3rd Edition, Marcel Dekker Inc.: New York, 1998; pages 499-518.
89. Wingerchuk C, Heim-Duthoy KL, Kasiske BL. Variability of Sandimmune pharmacokinetics in renal transplant patients. *Transplant Proc* 30(5):1656-1657, 1998.
90. Kasiske BL. Nonimmune therapies for chronic allograft rejection. *Graft* 1998. Proceedings of the American Society of Transplant Physicians Winter Symposium, January 1998.
91. Kasiske BL. The Role of Circulating Lipid Abnormalities in Chronic Renal Allograft Rejection. *Kidney Int* 1999; 56 (Suppl 7):S28-S30, 1999.
92. Kasiske BL. Section 16, Chapter 90, Chronic Transplant Rejection. In *Comprehensive Clinical Nephrology*, RJ Johnson and J Feehally (eds.), Mosby, London, 1999, pages 90.1-90.8.
93. B. Kasiske. Will chronic rejection impact the future of transplantation? [interview] [In Process Citation]. *Nephrol.News Issues* 13 (8):45-46, 1999.
94. Kasiske B, Charpentier B. Transplantation proceedings: Forward. *Transplant Proc* 31:1S, 1999.
95. Kasiske BL. Surrogate endpoints for clinical trials in renal transplantation. In Cochat (ed), *Immunosuppression under Trial*. Kluwer Academic Publishers, Lancaster, England, 1999.
96. Guijarro C, Blanco-Colio LM, Massy ZA, O'Donnell MP, Kasiske BL, Keane WF, Egido J: Lipophilic statins induce apoptosis of human vascular smooth muscle cells. *Kidney Int Suppl*. 71:S88-S91, 1999.
97. Massy ZA, Guijarro C, O'Donnell MP, Kim Y, Kashtan CE, Egido J, Kasiske BL, and Keane WF. The central role of nuclear factor-kappa B in mesangial cell activation. *Kidney Int Suppl* 71:S76-S79, 1999.
98. Neugarten J, Gallo G, Silbiger S, and Kasiske B. Glomerulosclerosis in aging humans is not influenced by gender. *Am.J.Kidney Dis.* 34 (5):884-888, 1999.
99. Oda H, Kasiske BL, O'Donnell MP, and Keane WF. Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells. *Kidney Int Suppl* 71:S202-S205, 1999.
100. Swan SK, Kasiske BL. Outcome and interventions in chronic renal disease: evidence from adequately designed clinical trials and meta-analysis. In *Mechanisms and management of chronic renal failure*. Oxford University Press, New York, 2000, pages 424-450.
101. Kasiske BL, Keane WF. Laboratory assessment of renal disease: Clearance, urinalysis, and renal

- biopsy. In: The Kidney. Sixth Edition, BM Brenner (ed), WB Saunders Company:Cambridge. Pages 1129-1170, 2000.
102. Kasiske BL. Cardiovascular disease after renal transplanation. *Semin Nephrol* 20(2):176-187, 2000.
 103. Kasiske BL. Preventing end-stage renal disease: fact or fiction? P Cochat (ed). *Transplantation and Changing Management of Organ Failure*, 77-95, Kluwer Academic Publishers, London, 2000.
 121. Kasiske BL, Danpanich E. Malignancies in renal transplant recipients. *Transplant Proc* 32:1499-1500, 2000.
 122. Kasiske BL, Chakkera H, Louis T, Ma JZ. Immunosuppressiom withdrawal in renal transplantation. *Transplant Proc* 32:1506-1507, 2000.
 123. Kasiske BL, Cardiovascular disease after renal transplantation. *Semin Nephrol* 20:176-187, 2000.
 124. Kasiske BL, Snyder J, Matas A, Collins A (for the USRDS). The impact of transplantation on survival with kidney failure (Chapter 11). In: *Clinical Transplantations 2000*. Cecka and Terasaki (eds), UCLA Immunogenetics Center, Los Angeles, CA, pages 135-143, 2001.
 125. Kasiske BL. The evaluation of prospective renal transplant recipients. In *Primer on Kidney Diseases*, A Greenberg (ed), Academic Press, New York, Pages 455-459, 2001.
 126. Silkensen JR, Kasiske BL. Immunosuppression withdrawal. *Curr Opin Organ Transplant* 6(2):169-174, 2001.
 127. Kasiske BL. The kidney in cardiovascular disease. *Ann Intern Med* 134:707-709, 2001.
 128. Andany MA, Kasiske BL: Dyslipidemia and its management after renal transplantation. *J.Nephrol.* 14 Suppl 4: S81-S88, 2001.
 129. Kasiske BL: Epidemiology of cardiovascular disease after renal transplantation. *Transplantation* 72: S5-S8, 2001.
 130. Matas AJ, Kasiske B, Miller L. Proposed guidelines for re-evaluation of patients on the waiting list for renal cadaver transplantation. *Transplantation* 73(5):811-812., 2002.
 131. Kasiske BL, Ballantyne CM. Cardiovascular risk factors associated with immunosuppression in renal transplantation. *Transplantation Reviews* 16(1):1-21, 2002.
 132. Kasiske BL, Chavers BM, Foley RN, Rosenberg ME, Swan SK, Gunderson DJ, Gillette A. The next five years. *Am J Kidney Dis* 39(1):193-194, 2002.
 133. Sahadevan M, Kasiske BL. Hyperlipidemia in kidney disease: Causes and consequences. *Curr Opin Nephrol Hypertens* 11(3):323-329, 2002.
 134. Kasiske BL. Ischemic heart disease after renal transplantation. *Kidney Int* 61(1):356-369,

2002.

135. Bostom AD, Brown RS, Jr., Chavers BM, Coffman TM, Cosio FG, Culver K, Curtis JJ, Danovitch GM, Everson GT, First MR, Garvey C, Grimm R, Hertz MI, Hricik DE, Hunsicker LG, Ibrahim H, Kasiske BL, Kennedy M, Klag M, Knatterud ME, Kobashigawa J, Lake JR, Light JA, Matas AJ, McDiarmid SV, Miller LW, Payne WD, Rosenson R, Sutherland DE, Tejani A, Textor S, Valentine HA, Wiesner RH: Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group. *Am J Transplant* 2:491-500, 2002.
136. Kasiske BL. Quiz page. Urinary obstruction. *Am J Kidney Dis* 39:xliv, 2002.
137. Adeva Andany M, Kasiske BL. Nutritional management of renal transplantation, *In* S Massry and J Kopple (eds), *Nutritional Management of Renal Disease* (in press).
138. Adeva Andany M, Kasiske BL. Care of the kidney transplant recipient. Vigilant monitoring creates the best outcome. *Postgraduate Medicine* 112(3):93-96, 101-102, 105-108 PASSIM, 2002.